Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells

Hiromitsu Araki, Yoshinori Tamada, Seiya Imoto, Ben Dunmore, Deborah Sanders, Sally Humphrey, Masao Nagasaki, Atsushi Doi, Yukiko Nakanishi, Kaori Yasuda, Yuki Tomiyasu, Kousuke Tashiro, Cristin Print, D. Stephen Charnock-Jones, Satoru Kuhara, Satoru Miyano

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Fenofibrate is a synthetic ligand for the nuclear receptor peroxisome proliferator-activated receptor (PPAR) alpha and has been widely used in the treatment of metabolic disorders, especially hyperlipemia, due to its lipid-lowering effect. The molecular mechanism of lipid-lowering is relatively well defined: an activated PPARα forms a PPAR-RXR heterodimer and this regulates the transcription of genes involved in energy metabolism by binding to PPAR response elements in their promoter regions, so-called "trans-activation". In addition, fenofibrate also has anti-inflammatory and anti-athrogenic effects in vascular endothelial and smooth muscle cells. We have limited information about the anti-inflammatory mechanism of fenofibrate; however, "trans-repression" which suppresses production of inflammatory cytokines and adhesion molecules probably contributes to this mechanism. Furthermore, there are reports that fenofibrate affects endothelial cells in a PPARα-independent manner. In order to identify PPARα-dependently and PPARα-independently regulated transcripts, we generated microarray data from human endothelial cells treated with fenofibrate, and with and without siRNA-mediated knock-down of PPARα. We also constructed dynamic Bayesian transcriptome networks to reveal PPARα-dependent and -independent pathways. Our transcriptome network analysis identified growth differentiation factor 15 (GDF15) as a hub gene having PPARα-independently regulated transcripts as its direct downstream children. This result suggests that GDF15 may be PPARα-independent master-regulator of fenofibrate action in human endothelial cells.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalAngiogenesis
Volume12
Issue number3
DOIs
Publication statusPublished - Sep 1 2009

Fingerprint

Fenofibrate
Peroxisome Proliferator-Activated Receptors
Endothelial cells
Endothelial Cells
Growth Differentiation Factor 15
Therapeutics
Anti-Inflammatory Agents
Genes
Lipids
PPAR alpha
Response Elements
Gene Expression Profiling
Bayesian networks
Transcription
Microarrays
Cytoplasmic and Nuclear Receptors
Electric network analysis
Hyperlipidemias
Vascular Smooth Muscle
Transcriptome

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Cite this

Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells. / Araki, Hiromitsu; Tamada, Yoshinori; Imoto, Seiya; Dunmore, Ben; Sanders, Deborah; Humphrey, Sally; Nagasaki, Masao; Doi, Atsushi; Nakanishi, Yukiko; Yasuda, Kaori; Tomiyasu, Yuki; Tashiro, Kousuke; Print, Cristin; Charnock-Jones, D. Stephen; Kuhara, Satoru; Miyano, Satoru.

In: Angiogenesis, Vol. 12, No. 3, 01.09.2009, p. 221-229.

Research output: Contribution to journalArticle

Araki, H, Tamada, Y, Imoto, S, Dunmore, B, Sanders, D, Humphrey, S, Nagasaki, M, Doi, A, Nakanishi, Y, Yasuda, K, Tomiyasu, Y, Tashiro, K, Print, C, Charnock-Jones, DS, Kuhara, S & Miyano, S 2009, 'Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells', Angiogenesis, vol. 12, no. 3, pp. 221-229. https://doi.org/10.1007/s10456-009-9142-8
Araki, Hiromitsu ; Tamada, Yoshinori ; Imoto, Seiya ; Dunmore, Ben ; Sanders, Deborah ; Humphrey, Sally ; Nagasaki, Masao ; Doi, Atsushi ; Nakanishi, Yukiko ; Yasuda, Kaori ; Tomiyasu, Yuki ; Tashiro, Kousuke ; Print, Cristin ; Charnock-Jones, D. Stephen ; Kuhara, Satoru ; Miyano, Satoru. / Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells. In: Angiogenesis. 2009 ; Vol. 12, No. 3. pp. 221-229.
@article{efe1da7ed8774fec8eea3f886be25cd9,
title = "Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells",
abstract = "Fenofibrate is a synthetic ligand for the nuclear receptor peroxisome proliferator-activated receptor (PPAR) alpha and has been widely used in the treatment of metabolic disorders, especially hyperlipemia, due to its lipid-lowering effect. The molecular mechanism of lipid-lowering is relatively well defined: an activated PPARα forms a PPAR-RXR heterodimer and this regulates the transcription of genes involved in energy metabolism by binding to PPAR response elements in their promoter regions, so-called {"}trans-activation{"}. In addition, fenofibrate also has anti-inflammatory and anti-athrogenic effects in vascular endothelial and smooth muscle cells. We have limited information about the anti-inflammatory mechanism of fenofibrate; however, {"}trans-repression{"} which suppresses production of inflammatory cytokines and adhesion molecules probably contributes to this mechanism. Furthermore, there are reports that fenofibrate affects endothelial cells in a PPARα-independent manner. In order to identify PPARα-dependently and PPARα-independently regulated transcripts, we generated microarray data from human endothelial cells treated with fenofibrate, and with and without siRNA-mediated knock-down of PPARα. We also constructed dynamic Bayesian transcriptome networks to reveal PPARα-dependent and -independent pathways. Our transcriptome network analysis identified growth differentiation factor 15 (GDF15) as a hub gene having PPARα-independently regulated transcripts as its direct downstream children. This result suggests that GDF15 may be PPARα-independent master-regulator of fenofibrate action in human endothelial cells.",
author = "Hiromitsu Araki and Yoshinori Tamada and Seiya Imoto and Ben Dunmore and Deborah Sanders and Sally Humphrey and Masao Nagasaki and Atsushi Doi and Yukiko Nakanishi and Kaori Yasuda and Yuki Tomiyasu and Kousuke Tashiro and Cristin Print and Charnock-Jones, {D. Stephen} and Satoru Kuhara and Satoru Miyano",
year = "2009",
month = "9",
day = "1",
doi = "10.1007/s10456-009-9142-8",
language = "English",
volume = "12",
pages = "221--229",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells

AU - Araki, Hiromitsu

AU - Tamada, Yoshinori

AU - Imoto, Seiya

AU - Dunmore, Ben

AU - Sanders, Deborah

AU - Humphrey, Sally

AU - Nagasaki, Masao

AU - Doi, Atsushi

AU - Nakanishi, Yukiko

AU - Yasuda, Kaori

AU - Tomiyasu, Yuki

AU - Tashiro, Kousuke

AU - Print, Cristin

AU - Charnock-Jones, D. Stephen

AU - Kuhara, Satoru

AU - Miyano, Satoru

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Fenofibrate is a synthetic ligand for the nuclear receptor peroxisome proliferator-activated receptor (PPAR) alpha and has been widely used in the treatment of metabolic disorders, especially hyperlipemia, due to its lipid-lowering effect. The molecular mechanism of lipid-lowering is relatively well defined: an activated PPARα forms a PPAR-RXR heterodimer and this regulates the transcription of genes involved in energy metabolism by binding to PPAR response elements in their promoter regions, so-called "trans-activation". In addition, fenofibrate also has anti-inflammatory and anti-athrogenic effects in vascular endothelial and smooth muscle cells. We have limited information about the anti-inflammatory mechanism of fenofibrate; however, "trans-repression" which suppresses production of inflammatory cytokines and adhesion molecules probably contributes to this mechanism. Furthermore, there are reports that fenofibrate affects endothelial cells in a PPARα-independent manner. In order to identify PPARα-dependently and PPARα-independently regulated transcripts, we generated microarray data from human endothelial cells treated with fenofibrate, and with and without siRNA-mediated knock-down of PPARα. We also constructed dynamic Bayesian transcriptome networks to reveal PPARα-dependent and -independent pathways. Our transcriptome network analysis identified growth differentiation factor 15 (GDF15) as a hub gene having PPARα-independently regulated transcripts as its direct downstream children. This result suggests that GDF15 may be PPARα-independent master-regulator of fenofibrate action in human endothelial cells.

AB - Fenofibrate is a synthetic ligand for the nuclear receptor peroxisome proliferator-activated receptor (PPAR) alpha and has been widely used in the treatment of metabolic disorders, especially hyperlipemia, due to its lipid-lowering effect. The molecular mechanism of lipid-lowering is relatively well defined: an activated PPARα forms a PPAR-RXR heterodimer and this regulates the transcription of genes involved in energy metabolism by binding to PPAR response elements in their promoter regions, so-called "trans-activation". In addition, fenofibrate also has anti-inflammatory and anti-athrogenic effects in vascular endothelial and smooth muscle cells. We have limited information about the anti-inflammatory mechanism of fenofibrate; however, "trans-repression" which suppresses production of inflammatory cytokines and adhesion molecules probably contributes to this mechanism. Furthermore, there are reports that fenofibrate affects endothelial cells in a PPARα-independent manner. In order to identify PPARα-dependently and PPARα-independently regulated transcripts, we generated microarray data from human endothelial cells treated with fenofibrate, and with and without siRNA-mediated knock-down of PPARα. We also constructed dynamic Bayesian transcriptome networks to reveal PPARα-dependent and -independent pathways. Our transcriptome network analysis identified growth differentiation factor 15 (GDF15) as a hub gene having PPARα-independently regulated transcripts as its direct downstream children. This result suggests that GDF15 may be PPARα-independent master-regulator of fenofibrate action in human endothelial cells.

UR - http://www.scopus.com/inward/record.url?scp=70349510747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349510747&partnerID=8YFLogxK

U2 - 10.1007/s10456-009-9142-8

DO - 10.1007/s10456-009-9142-8

M3 - Article

C2 - 19357976

AN - SCOPUS:70349510747

VL - 12

SP - 221

EP - 229

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 3

ER -